There’s been a lot of news recently about roadrunners, and I’ll be talking about a few of them as well as a few that aren’t so well known.
The new ones are all coming up in the coming weeks, so stay tuned.
But if you’re looking for a little more detail, I’ll provide the first five from the new batch here.
The first is the new drug-resistant strain of superbug MRSA.
This is a very good news story.
MRSA is the most common superbug that can kill people.
But it’s been on the rise for some time, and this new strain was the first to jump into the fray.
This particular MRSA strain is very difficult to kill, but the treatment regimen is so restrictive that it’s also very risky.
This MRSA drug is a combination of drugs, one of which is called cefuroxime, which is a medication that’s used to treat a rare but severe form of pneumonia called pneumococcus pneumoniae.
But that’s not all that it does.
There are other treatments that it also uses as well, including antibiotics, and they’re usually the ones that you’re most likely to be using when you’re treating a pneumonia.
In a perfect world, these drugs would also help treat a very rare but even more serious form of the MRSA infection called Enterococcus faecium.
So it’s not like you’re getting one drug that works and another drug that doesn’t.
MRSE is resistant to a variety of antibiotics and is also resistant to cefotaxime, the antibiotic that’s the standard treatment for MRSA, which makes it more likely to cause death.
So, we’re now in a situation where we have to try to treat both the very common MRSA form and the new MRSE strain.
So if you have an infection like that, you’ll want to be on cefoxitin, the drug used to combat the very rare MRSA version.
Cefoxifen can cause side effects, but they’re not very serious.
So for the new superbug, cefosoxime, they’ve created a drug that has a slightly higher potency.
So this drug is going to be the standard of care for a lot more people than the drug that we’re currently using.
And that means that we’ll be seeing a lot fewer of these infections getting treated.
The second is a new strain of MRSA that’s resistant to antibiotics.
This new strain, MRSA-20, has been found to be resistant to the antibiotics cefazolin and cefenamide.
That means it’s resistant in the human body to the very best antibiotics.
So we have a very difficult situation in India right now, because most of the drugs that we are using are very expensive and don’t have any efficacy at all against MRSA infections.
That’s why we’re seeing an increase in MRSA cases, but also the emergence of these resistant strains.
The third is a strain that has also been found resistant to most antibiotics.
That one is MRSA 17, which has been in use for a long time, but it’s the first strain to be found resistant.
This one is very, very difficult for us to treat.
The drugs that are being used against MRSE have very low efficacy, so we need to try more aggressive and very specific treatments, which means we’re going to see an increase of new MRSA patients coming in.
The fourth strain is MRSE-19.
This strain has been resistant to all of the antibiotics that have been tested against it.
This has to do with the fact that MRSE has an unusually large cell size, and that makes it easier for it to escape from the body.
So that’s why MRSE patients are coming in to hospital, and we’ve also seen some MRSE cases in hospitals.
The fifth strain is a resistance to a different type of antibiotic.
MR-20 is resistant only to cephalosporins.
These are antibiotics that we already use against MR-19, and cephasporin is a drug we use to treat pneumonia.
We can’t use cephesporins against MR19, because it’s a very serious infection, but we can use cefamomast to treat it, which doesn’t kill it.
So cefampronavir, which we’re also seeing resistance to, can be used to try and treat MRSE, but that only kills MRSE.
So you have a situation in which there are only a few drugs that can treat MRSA and MRSE strains that are resistant to them, and those drugs are all expensive.
So as the numbers of MRSE infections grow, the prices for antibiotics will also go up.
And so we’re in a very desperate situation, because we don’t know how to treat the MRSE problems, and the cost of drugs is going